Vistagen Therapeutics, Inc. (VTGN) insider trading.
In Q3 2026, insiders at Vistagen Therapeutics, Inc. reported 3 non-derivative transactions on 5 Forms 3, 4 and 5: 0 open-market purchases and 0 sales.
- Transactions
- 3
- Purchases (P)
- 0
- Sales (S)
- 0
- Net shares, P minus S
- 0
- Insiders
- 3
- Last filed
- 2026-07-02
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Singh Shawn | Director, Officer · President and CEO | 1 | 0 | 0 |
| Tressler Nick B. | Officer · Chief Financial Officer | 1 | 0 | 0 |
| Adler Reid G. | Officer · Chief Legal Officer | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Singh Shawn | A (A) | 36,818 | $0.19 | 54,846 | Form 4 |
| 2026-06-30 | Tressler Nick B. | A (A) | 11,712 | $0.19 | 11,712 | Form 4 |
| 2026-06-30 | Adler Reid G. | A (A) | 36,818 | $0.19 | 60,868 | Form 4 |
Transaction codes in this quarter
Get VTGN insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1411685&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · VTGN company page · Vistagen Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Vistagen Therapeutics, Inc. (VTGN)?
In Q3 2026, insiders at Vistagen Therapeutics, Inc. reported 3 non-derivative transactions on 5 Forms 3, 4 and 5: 0 open-market purchases and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Vistagen Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/vtgn.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.